IRWD - Ironwood Pharmaceuticals, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company which is focused on advancing innovative product opportunities in areas of large unmet needs such as constipation, gastrointestinal disorders, hyperuricemia, among others.
IPO Date: February 3, 2010
Sector: Healthcare
Industry: Drug Manufacturers
Market Cap: $619.65M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.24 | 2.43%
Avg Daily Range (30 D): $0.10 | 2.34%
Avg Daily Range (90 D): $0.13 | 3.40%
Institutional Daily Volume
Avg Daily Volume: 1.34M
Avg Daily Volume (30 D): 1.46M
Avg Daily Volume (90 D): 1.67M
Trade Size
Avg Trade Size (Sh.): 140
Avg Trade Size (Sh.) (30 D): 140
Avg Trade Size (Sh.) (90 D): 133
Institutional Trades
Total Institutional Trades: 7,776
Avg Institutional Trade: $1.92M
Avg Institutional Trade (30 D): $1.78M
Avg Institutional Trade (90 D): $1.71M
Avg Institutional Trade Volume: .18M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $2.5M
Avg Closing Trade (30 D): $1.8M
Avg Closing Trade (90 D): $1.67M
Avg Closing Volume: 260.53K
 
News
Oct 7, 2026 @ 1:57 PM
Will Linzess Continue to Aid Ironwood's Top-Line G...
Source: Na
Sep 30, 2026 @ 3:08 PM
PGEN vs. IRWD: Which Biotech Stock Offers Better G...
Source: Na
Feb 9, 2026 @ 6:55 PM
3 Stocks Trading Near $5 With Massive Earnings Ups...
Source: Chris Markoch
Jan 5, 2026 @ 1:36 PM
Stock Market Today: S&P 500, Nasdaq, WTI Crude Fut...
Source: Rishabh Mishra
Jan 2, 2026 @ 6:30 PM
Ironwood Finds a New Floor as LINZESS Net Pricing ...
Source: Timothy Fries
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $.8 $.31 $.25
Diluted EPS $.77 $.31 $.24
Revenue $389.32M $113.04M $106.51M
Gross Profit
Net Income / Loss $129.87M $51.29M $40.77M
Operating Income / Loss $234.17M $79.31M $72.57M
Cost of Revenue
Net Cash Flow $122.28M $-5.12M $5.12M
PE Ratio